ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
DRUG: ICP-022|DRUG: Chlorambucil|DRUG: Rituximab
Progression Free Survival (PFS), Progress-free survival (PFS) was evaluated by the independent review board (IRC) against the IWCLL2018 criteria (Hallek et al., 2018) and the revised lymphoma mitigation assessment criteria (Cheson et al., 2014)., Up to 5 years
Objective Response Rate (ORR), Up to 5 years|Duration Of Response (DOR), Up to 5 years|Overall Survival (OS), Up to 5 years
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.